Humacyte, Inc. (NASDAQ:HUMAW) Sees Significant Increase in Short Interest

Humacyte, Inc. (NASDAQ:HUMAW) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 24,488 shares, an increase of 614.1% from the June 15th total of 3,429 shares. Based on an average daily trading volume, of 51,673 shares, the days-to-cover ratio is currently 0.5 days.

Humacyte Stock Down 10.9%

Shares of HUMAW stock traded down $0.00 during trading hours on Monday, reaching $0.01. 156 shares of the stock traded hands, compared to its average volume of 18,100. Humacyte has a 1-year low of $0.00 and a 1-year high of $0.60. The business has a fifty day moving average price of $0.04 and a 200 day moving average price of $0.08.

Humacyte Company Profile

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.